Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

Similar articles for PubMed (Select 23658823)

1.

Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.

Pal SK, Nelson RA, Vogelzang N.

PLoS One. 2013 May 3;8(5):e63341. doi: 10.1371/journal.pone.0063341. Print 2013.

2.

A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.

Nelson RA, Vogelzang N, Pal SK.

Clin Genitourin Cancer. 2013 Sep;11(3):303-10. doi: 10.1016/j.clgc.2013.04.011. Epub 2013 May 4.

3.

Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.

Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN Jr.

Clin Genitourin Cancer. 2012 Jun;10(2):93-8. doi: 10.1016/j.clgc.2012.01.007. Epub 2012 Feb 28.

PMID:
22382008
4.

Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.

Culp SH, Karam JA, Wood CG.

Urol Oncol. 2014 Jul;32(5):561-8. doi: 10.1016/j.urolonc.2013.12.003. Epub 2014 Apr 4.

PMID:
24709415
5.

Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.

Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ.

Anticancer Res. 2014 May;34(5):2405-11.

PMID:
24778051
6.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM.

Ann Oncol. 2011 May;22(5):1048-53. doi: 10.1093/annonc/mdq563. Epub 2010 Nov 29.

7.

The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database.

Vaishampayan U, Vankayala H, Vigneau FD, Quarshie W, Dickow B, Chalasani S, Schwartz K.

Clin Genitourin Cancer. 2014 Apr;12(2):124-9. doi: 10.1016/j.clgc.2013.09.007. Epub 2013 Sep 28.

8.

Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?

Giuliani J, Drudi F.

Cancer Biother Radiopharm. 2012 Oct;27(8):513-8. doi: 10.1089/cbr.2012.1250. Epub 2012 Jun 27.

PMID:
22738404
9.

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD.

World J Urol. 2013 Dec;31(6):1535-9. doi: 10.1007/s00345-012-1001-3. Epub 2012 Dec 8.

PMID:
23223962
10.

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.

Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ.

Cancer. 2008 Nov 1;113(9):2457-63. doi: 10.1002/cncr.23851.

11.

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY.

J Urol. 2011 Jan;185(1):60-6. doi: 10.1016/j.juro.2010.09.012. Epub 2010 Nov 12.

PMID:
21074201
12.

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG.

J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.

PMID:
17868729
13.

Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.

Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S, Leppert JT.

Int J Cancer. 2014 May 1;134(9):2245-52.

14.

Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.

You D, Jeong IG, Song C, Lee JL, Hong B, Hong JH, Ahn H, Kim CS.

Jpn J Clin Oncol. 2015 Jan;45(1):96-102. doi: 10.1093/jjco/hyu171. Epub 2014 Oct 23.

PMID:
25341544
15.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY.

Eur Urol. 2014 Jun;65(6):1086-92. doi: 10.1016/j.eururo.2013.07.031. Epub 2013 Jul 30.

PMID:
23916693
16.

Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.

Pal SK, Hsu J, Hsu S, Hu J, Bergerot P, Carmichael C, Saikia J, Liu X, Lau C, Twardowski P, Figlin RA, Yuh BF.

J Geriatr Oncol. 2013 Apr;4(2):128-33.

17.

Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.

Stroup SP, Raheem OA, Palazzi KL, Liss MA, Mehrazin R, Kopp RP, Patel N, Cohen SA, Park SK, Patterson AL, Kane CJ, Millard F, Derweesh IH.

Urology. 2013 Apr;81(4):805-11. doi: 10.1016/j.urology.2012.10.054. Epub 2013 Feb 13.

PMID:
23414694
18.

Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).

Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK.

BJU Int. 2014 May;113(5b):E67-74. doi: 10.1111/bju.12442. Epub 2014 Feb 14.

19.

Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.

Takagi T, Kondo T, Kennoki T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K.

Jpn J Clin Oncol. 2013 Apr;43(4):439-43. doi: 10.1093/jjco/hys234. Epub 2013 Jan 9.

20.

Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA.

BJU Int. 2010 Jul;106(2):218-23. doi: 10.1111/j.1464-410X.2009.09079.x. Epub 2009 Nov 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk